Share on facebook Share on Twitter Share on Google Plus Share This

Hypertrophic Cardiomyopathy Center
and Research Institute

Research + Clinical Trials

In addition to providing world-class care for patients with HCM and their family members, the Tufts Medical Center HCM Center is at the forefront of scientific clinical research aimed at improving diagnosis and management strategies for all patients with hypertrophic cardiomyopathy. Our team is currently involved in a variety of investigative research projects focused on identifying mechanisms of HCM disease expression which may ultimately lead to future therapies to improve the lives of our patients. In addition, we are a leading Center for clinical trials evaluating the efficacy of a number of recent novel drug therapies aimed at mitigating limiting symptoms in patients with HCM.  

At Tufts Medical Center, hypertrophic cardiomyopathy is a treatable genetic heart disease compatible with normal or extended longevity (often without the requirement of major treatments). Our national/international HCM Referral Center has established this principle for patients with this genetic disease over the past 15 years.

Interested in Participating in a Study or Clinical Trial?

If you are a patient interested in hearing more about our research or participating in one of our studies, please contact our Center and leave a message with Sue Costa. One of our team members will reach out to you promptly. Sue can be reached at or 617-636-8066 (opt. 1).

The following is a sampling of our most current research:

1.       Signaling Pathways Within HCM

Research study of the heart muscle removed after surgical septal myectomy evaluating the HCM disease process using network theory methods to identify important biologic interactions unique to HCM that promote increased wall thickness and heart muscle scarring. This may ultimately led to developing novel treatments aimed at improving symptoms or mitigating disease progression. 

2.       Effect of Eleclazine (GS-6615) on Exercise Capacity with Symptomatic Hypertrophic Cardiomyopathy (Liberty-HCM)

Dr. Maron is the US primary investigator for an international clinical trial which is evaluating a novel drug called eleclazine, developed by Gilead Sciences, in the treatment of limiting symptoms in patients with HCM. Learn more >

3.       Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamis of MYK-461

The Tufts HCM Institute is participating in early human clinical studies evaluating the safety and tolerability of a novel drug (MYK-461), developed for the treatment of limiting symptoms in patients with HCM. Learn more >

4.       Novel Markers of Prognosis in HCM (HCMR)

National Heart, Lung and Blood Institute (NHLBI) sponsored international study evaluating demographic, clinical, and novel CMR, genetic and biomarker variables to develop a predictive model of cardiovascular outcomes within HCM. Learn more >

5.       3D-Printing Model for Surgical Myectomy Planning

Study to evaluate the efficacy of a 3-D printed model to help guide surgical planning for septal myectomy.  A model that accurately reproduces an individual patient anatomy may ultimately lead to shorter cardiopulmonary bypass times as well as improve surgical training of the unique techniques required for this operation.  

The HCM Center and Research Institute has achieved a particularly high level of clinical research activity, providing a model for contemporary diagnosis, natural history and clinical course and treatment of HCM which has resulted in low mortality and survival with high quality of life. These are the most important peer-reviewed published papers (with citations) from the last 5 years: (Authors in BOLD are Tufts MC physicians)

Maron BJ, Rowin EJ, Casey SA, Maron MS.  How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low morality shaped by 50 years of clinical research and practice.  JAMA Cardiol.  2016;1:98-105.

Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, et al.  Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies.  J Am Coll Cardiol.  2015;65:1915-1928.

Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al.  Hypertrophic cardiomyopathy with left ventricular apical aneurysm:  Implications for risk stratification and management.  J Am Coll Cardiol 2017;69:761-773.

Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic  resonance imaging in hypertrophic cardiomyopathy.  Circulation 2015;132:292-8.

Semarian C, Ingles J, Maron MS, Maron BJ.  New perspectives on the prevalence of hypertrophic cardiomyopathy.  J Am Coll Cardiol 2015;65:1249-54.

Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg 2017;6:353-363.

Maron BJ, Maron MS, Rowin EJ.  Perspectives on the overall risk of living with hypertrophic cardiomyopathy.  Circulation.  2017; 135: 2317-2319.

Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy:  present and future, with translation into contemporary cardiovascular medicine.  J Am Coll Cardiol 2014;64:83-99.

Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ.  Interaction of adverse disease related pathways in hypertrophic cardiomyopathy.  Am J Cardiol, in press.

Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ.  Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy.  Circulation, in press.

Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM 3rd, et al.  Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities:  task force 3:  hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis:  a scientific statement from the American Heart Association and American College of Cardiology.  J Am Coll Cardiol.  2015; 66: 2362-2371.

Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS.  Independent assessment of the European society of cardiology sudden death risk model for hypertrophic cardiomyopathy.  Am J Cardiol. 2015; 166: 757-64

Maron MS, Hellawell JL, Lucove JC, Franzanek-Far R, Olivotto I.  Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States.  Am J Cardiol. 2016; 117:1651-54.

Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO.  Sudden deaths in young competitive athletes:  analysis of 1866 deaths in the United States, 1980-2006.  Circulation 2009; 119-1085-1092.

Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, et al.  Risk Stratification and outcome of patients with hypertrophic cardiomyopathy ≥ 60 years of age.  Circulation 2013;127:585-93.

Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, Maron MS.  Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies.  Circulation. 2016;133:62-73.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.  JAMA.  2007;298:405-412.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haast T, et al.  Prognostic value of quantative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.  Circulation.  2014;130:484-495.

Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D.  Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy.  Circ Heart Fail 2010;3:574-9.

Rowin EJ, Maron BJ, Olivotto I, Maron MS.  Role of exercise testing in hypertrophic cardiomyopathy.  State-of-the art.  JACC Imag, in press.

Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al.  Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy.  J Am Coll Cardiol 2016;67:1399-409.

Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, et al.  Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy.  Circ Heart Fail 2017;10:e003689.

Maron BJ, Maron MS.  Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.  Heart Rhythm.  2016;13:1155-1165.

Sue Costa is the coordinator in the Hypertrophic Cardiomyopathy Center at Tufts Medical Center in downtown Boston, MA.

For an appointment, contact our HCM Center Coordinator Sue Costa. She will help you.

Phone: 617-636-8066<br>Email:

Father, son Cardiovascular Specialists, Barry and Martin Maron, spread the word that HCM is now a manageable disease at Tufts Medical Center in downtown Boston, MA.

The father-son duo that’s changing a cardiac narrative

Drs. Barry and Marty Maron want you to know something: HCM is now a treatable disease compatible with normal longevity and a good quality of life.

Read the article